Classical Pathway

临床试验

计划入组 144 人 · 首次发布于 2024 年 4 月 17 日

Enrolling By Invitation

NCT06723106

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

计划入组 144 人 · 首次发布于 2024 年 12 月 9 日

已完成

NCT00432939

Primary Hyperparathyroidism: Non-classical Manifestations

计划入组 58 人 · 首次发布于 2007 年 2 月 8 日

药物

查看全部 83 →

classical homocystinuria

Biotech

Investigational

Riliprubart

生产企业：Sanofi

相关疾病：Chronic Inflammatory Demyelinating Polyneuropathy

UPR pathway modulators (Proteostasis)

机构

查看全部 18 →

Pathway Therapeutics, Inc.

United States

Erasca

United States

UNIVERSITY OF WISCONSIN-MADISON

United States

资讯

查看全部 4947 →

去年

ANX007 Shows Promise in Preserving Vision in Dry AMD Patients with Geographic Atrophy

2年前

Annexon's ANX007 Shows Promise in Protecting Vision in Geographic Atrophy

去年

临床试验

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

Primary Hyperparathyroidism: Non-classical Manifestations

药物

classical homocystinuria

Riliprubart

UPR pathway modulators (Proteostasis)

机构

Pathway Therapeutics, Inc.

Erasca

UNIVERSITY OF WISCONSIN-MADISON

资讯

ANX007 Shows Promise in Preserving Vision in Dry AMD Patients with Geographic Atrophy

Annexon's ANX007 Shows Promise in Protecting Vision in Geographic Atrophy

Dianthus Therapeutics Completes Enrollment in Phase 2 MaGic Trial for Generalized Myasthenia Gravis Treatment